GW 5950X
Latest Information Update: 02 Aug 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline; Vertex Pharmaceuticals
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
- 24 Aug 2000 Preclinical development for HIV-1 infections in USA (Unknown route)